Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

Journal of Hepatology

Volumn 69, Issue 1, 2018, Pages 18-24

  Petta, Salvatore ^a   Adinolfi, Luigi Elio ^b   Fracanzani, Anna Ludovica ^c   Rini, Francesca ^a   Caldarella, Rosalia ^a   Calvaruso, Vincenza ^a   Cammà, Calogero ^a   Ciaccio, Marcello ^a   Di Marco, Vito ^a   Grimaudo, Stefania ^a   Licata, Anna ^a   Marrone, Aldo ^b   Nevola, Riccardo ^b   Pipitone, Rosaria Maria ^a   Pinto, Antonio ^a   Rinaldi, Luca ^b   Torres, Daniele ^a   Tuttolomondo, Antonino ^a   Valenti, Luca ^c   Fargion, Silvia ^c   Craxì, Antonio ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; DAA; HCV; SVR

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL; DACLATASVIR; DASABUVIR; GLUCOSE; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GLUCOSE HOMEOSTASIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SUSTAINED VIROLOGIC RESPONSE; VIRAL CLEARANCE; CAROTID ARTERY DISEASE; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; FOLLOW UP; HEPACIVIRUS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85044589215     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.02.015     Document Type: Article

References (50)

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
2. Negro, F., Forton, D., Craxì A., Sulkowski, M.S., Feld, J.J., Manns, M.P., Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
3. Younossi, Z., Park, H., Henry, L., Adeyemi, A., Stepanova, M., Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
4. Targher, G., Bertolini, L., Padovani, R., Rodella, S., Arcaro, G., Day, C., Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46 (2007), 1126–1132.
5. Adinolfi, L.E., Restivo, L., Zampino, R., Guerrera, B., Lonardo, A., Ruggiero, L., et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221 (2012), 496–502.
6. Petta, S., Torres, D., Fazio, G., Cammà C., Cabibi, D., Di Marco, V., et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55 (2012), 1317–1323.
7. Vassalle, C., Masini, S., Bianchi, F., Zucchelli, G.C., Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90 (2004), 565–566.
8. Alyan, O., Kacmaz, F., Ozdemir, O., Deveci, B., Astan, R., Celebi, A.S., et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 72 (2008), 1960–1965.
9. Butt, A.A., Xiaoqiang, W., Budoff, M., Leaf, D., Kuller, L.H., Justice, A.C., Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49 (2009), 225–232.
10. Maruyama, S., Koda, M., Oyake, N., Sato, H., Fujii, Y., Horie, Y., et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58 (2013), 11–15.
11. Hsu, Y.H., Muo, C.H., Liu, C.Y., Tsai, W.C., Hsu, C.C., Sung, F.C., et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 62 (2015), 519–525.
12. Liao, C.C., Su, T.C., Sung, F.C., Chou, W.H., Chen, T.L., Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One, 7, 2012, e31527.
13. Guiltinan, A.M., Kaidarova, Z., Custer, B., Orland, J., Strollo, A., Cyrus, S., et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 167 (2008), 743–750.
14. Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y., et al., R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206 (2012), 469–477.
15. Petta, S., Craxi, A., Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. Gut, 2017, 10.1136/gutjnl-2017-314505 [pii: gutjnl-2017-314505].
16. Petta, S., Maida, M., Macaluso, F.S., Barbara, M., Licata, A., Craxì A., et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150 (2016), 145–155.
17. Hsu, C.S., Kao, J.H., Chao, Y.C., Lin, H.H., Fan, Y.C., Huang, C.J., et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 38 (2013), 415–423.
18. Hsu, Y., Lin, J., Ho, H., Kao, Y., Huang, Y., Hsiao, N., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
19. Lee, M.H., Yang, H.I., Wang, C.H., Jen, C.L., Yeh, S.H., Liu, C.J., Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 41 (2010), 2894–2900.
20. Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., et al., ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156 e2.
21. Cacoub, P., Nahon, P., Layese, R., Bourcier, V., Cagnot, C., Marcellin, P., et al. HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort. J Hepatol 66 (2017), S1–S32.
22. Singer, A.W., Osinusi, A., Brainard, D.M., Chokkalingam, A.P., Gilead Sciences, Foster City, United States. Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study. J Hepatol 66 (2017), S95–S332.
23. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000 (2000), S4–S19.
24. Kanters, S.D., Algra, A., van Leeuwen, M.S., Banga, J.D., Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 28 (1997), 665–671.
25. Smilde, T.J., Wollersheim, H., Van Langen, H., Stalenhoef, A.F., Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci 93 (1997), 317–324.
26. Espeland, M.A., Craven, T.E., Riley, W.A., Corson, J., Romont, A., Furberg, C.D., Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 27 (1996), 480–485.
27. Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., et al. Collaborators on the sitagliptin preventive study of intima-media thickness evaluation (SPIKE) trial. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care 39 (2016), 455–464.
28. Oyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., et al., PROLOGUE Study Investigators. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med, 13, 2016, e1002051.
29. Simon, A., Gariepy, J., Chironi, G., Megnien, J., Levenson, J., Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20 (2002), 159–169.
30. Simon, A., Chironi, G., Levenson, J., Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J 28 (2007), 2967–2971.
31. Chambless, L.E., Heiss, G., Folsom, A.R., Rosamond, W., Szklo, M., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987–1993. Am J Epidemiol 146 (1997), 483–494.
32. Chambless, L.E., Folsom, A.R., Clegg, L.X., Sharrett, A.R., Shahar, E., et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151 (2000), 478–487.
33. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
34. Documento di indirizzo dell'associazione italiana per lo studio del fegato per l'uso razionale dei farmaci anti-HCV disponibili in italia available at http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2017.aspx.
35. Mahale, P., Engels, E.A., Li, R., Torres, H.A., Hwang, L.Y., Brown, E.L., et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut, 2017, 10.1136/gutjnl-2017-313983 [pii: gutjnl-2017-313983].
36. Innes, H.A., McDonald, S.A., Dillon, J.F., Allen, S., Hayes, P.C., Goldberg, D., et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
37. Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49 (2009), 739–744.
38. Romero-Gómez, M., Fernández-Rodríguez, C.M., Andrade, R.J., Diago, M., Alonso, S., Planas, R., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 48 (2008), 721–727.
39. Hum, J., Jou, J.H., Green, P.K., Berry, K., Lundblad, J., Hettinger, B.D., et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care 40 (2017), 1173–1180.
40. Sun, H.Y., Cheng, P.N., Tseng, C.Y., Tsai, W.J., Chiu, Y.C., Young, K.C., Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut, 2017, 10.1136/gutjnl-2017-313832 [pii: gutjnl-2017-313832].
41. Hofer, H., Bankl, H.C., Wrba, F., Steindl-Munda, P., Peck-Radosavljevic, M., Osterreicher, C., et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 97 (2002), 2880–2885.
42. Bugianesi, E., Salamone, F., Negro, F., The interaction of metabolic factors with HCV infection: does it matter?. J Hepatol 56 (2012), S56–S65.
43. Vanni, E., Abate, M.L., Gentilcore, E., Hickman, I., Gambino, R., Cassader, M., et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50 (2009), 697–706.
44. Rehermann, B., Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19 (2013), 859–868.
45. Petit, J.M., Minello, A., Jooste, V., Bour, J.B., Galland, F., Duvillard, L., et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 90 (2005), 2240–2243.
46. Cua, I.H., Hui, J.M., Bandara, P., Kench, J.G., Farrell, G.C., McCaughan, G.W., et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46 (2007), 66–73.
47. Durante-Mangoni, E., Zampino, R., Marrone, A., Tripodi, M.F., Rinaldi, L., Restivo, L., et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 24 (2006), 1349–1357.
48. Serres, L., Vasseur, P., Tougeron, D., Gand, E., Chagneau-Derrode, C., Charier, F., et al. Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution. Eur J Gastroenterol Hepatol 27 (2015), 1286–1292.
49. González-Reimers, E., Quintero-Platt, G., Martín-González, C., Pérez-Hernández, O., Romero-Acevedo, L., Santolaria-Fernández, F., Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 22 (2016), 4427–4437.
50. Petta, S., Valenti, L., Marchesini, G., Di Marco, V., Licata, A., Cammà C., et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One, 8, 2013, e74089.